{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:06:15Z","timestamp":1786982775950,"version":"build-2736575974"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,10,7]],"date-time":"2020-10-07T00:00:00Z","timestamp":1602028800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,10,7]],"date-time":"2020-10-07T00:00:00Z","timestamp":1602028800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Mitacs Globalink","award":["#FR41232"],"award-info":[{"award-number":["#FR41232"]}]},{"name":"Mitacs Globalink","award":["#FR41232"],"award-info":[{"award-number":["#FR41232"]}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"crossref","award":["#2019K1A3A1A73079569"],"award-info":[{"award-number":["#2019K1A3A1A73079569"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs R D"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s40268-020-00323-2","type":"journal-article","created":{"date-parts":[[2020,10,7]],"date-time":"2020-10-07T11:03:09Z","timestamp":1602068589000},"page":"343-358","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Comparisons of Four Protein-Binding Models Characterizing the Pharmacokinetics of Unbound Phenytoin in Adult Patients Using Non-Linear Mixed-Effects Modeling"],"prefix":"10.1007","volume":"20","author":[{"given":"Heajin","family":"Jun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Rong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catharina","family":"Yih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4548-9746","authenticated-orcid":false,"given":"Tony K. L.","family":"Kiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,7]]},"reference":[{"key":"323_CR1","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1177\/2042098611411127","volume":"2","author":"JA French","year":"2011","unstructured":"French JA, Gazzola DM. New generation antiepileptic drugs: what do they offer in terms of improved tolerability and safety? Ther Adv Drug Saf. 2011;2:141\u201358.","journal-title":"Ther Adv Drug Saf"},{"key":"323_CR2","first-page":"508","volume":"25","author":"BW Abou-Khalil","year":"2019","unstructured":"Abou-Khalil BW. Update on antiepileptic drugs 2019. Continuum (Minneap Minn). 2019;25:508\u201336.","journal-title":"Continuum (Minneap Minn)"},{"key":"323_CR3","unstructured":"Phenytoin: Drug Usage Statistics, United States, 2007\u20132017. ClinCalc. 2017. https:\/\/clincalc.com\/DrugStats\/Drugs\/Phenytoin. Accessed 12 Jul 2020."},{"key":"323_CR4","unstructured":"Morita DA, Glauser TA. Phenytoin and Fosphenytoin. In: Wyllie E, Cascino GD, Gidal BE, Goodkin HP, editors. Wyllie's treatment of epilepsy. 5 ed. Philadelphia: Wolters Kluwer, Lippincott Williams & Wilkins; 2011. pp. 630\u2013647."},{"key":"323_CR5","doi-asserted-by":"crossref","first-page":"153","DOI":"10.2165\/00003088-197904030-00001","volume":"4","author":"A Richens","year":"1979","unstructured":"Richens A. Clinical pharmacokinetics of phenytoin. Clin Pharmacokinet. 1979;4:153\u201369.","journal-title":"Clin Pharmacokinet"},{"key":"323_CR6","first-page":"1401","volume":"24","author":"M Bajpai","year":"1996","unstructured":"Bajpai M, Roskos LK, Shen DD, Levy RH. Roles of cytochrome P4502C9 and cytochrome P4502C19 in the stereoselective metabolism of phenytoin to its major metabolite. Drug Metab Dispos. 1996;24:1401\u20133.","journal-title":"Drug Metab Dispos"},{"key":"323_CR7","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/0006-291X(91)91680-B","volume":"175","author":"ME Veronese","year":"1991","unstructured":"Veronese ME, Mackenzie PI, Doecke CJ, McManus ME, Miners JO, Birkett DJ. Tolbutamide and phenytoin hydroxylations by cDNA-expressed human liver cytochrome P4502C9. Biochem Biophys Res Commun. 1991;175:1112\u20138.","journal-title":"Biochem Biophys Res Commun"},{"key":"323_CR8","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.1365-2125.1991.tb05499.x","volume":"31","author":"CJ Doecke","year":"1991","unstructured":"Doecke CJ, Veronese ME, Pond SM, Miners JO, Birkett DJ, Sansom LN, McManus ME. Relationship between phenytoin and tolbutamide hydroxylations in human liver microsomes. Br J Clin Pharmacol. 1991;31:125\u201330.","journal-title":"Br J Clin Pharmacol"},{"key":"323_CR9","first-page":"175","volume":"77","author":"FL Kozelka","year":"1943","unstructured":"Kozelka FL, Hine CH. Degradation products of dilantin. J Pharmacol Exp Ther. 1943;77:175\u20139.","journal-title":"J Pharmacol Exp Ther"},{"key":"323_CR10","first-page":"455","volume":"3","author":"N Gerber","year":"1972","unstructured":"Gerber N, Wagner JG. Explanation of dose-dependent decline of diphenylhydantoin plasma levels by fitting to the integrated form of the Michaelis-Menten equation. Res Commun Chem Pathol Pharmacol. 1972;3:455\u201366.","journal-title":"Res Commun Chem Pathol Pharmacol"},{"key":"323_CR11","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1528-1167.2012.03671.x","volume":"54","author":"MJ Brodie","year":"2013","unstructured":"Brodie MJ, Mintzer S, Pack AM, Gidal BE, Vecht CJ, Schmidt D. Enzyme induction with antiepileptic drugs: cause for concern? Epilepsia. 2013;54:11\u201327.","journal-title":"Epilepsia"},{"key":"323_CR12","doi-asserted-by":"crossref","first-page":"8","DOI":"10.9740\/mhc.2015.01.008","volume":"6","author":"M Marvanova","year":"2016","unstructured":"Marvanova M. Pharmacokinetic characteristics of antiepileptic drugs (AEDs). Ment Health Clin. 2016;6:8\u201320.","journal-title":"Ment Health Clin"},{"key":"323_CR13","unstructured":"Phenytoin\/fosphenytoin. In: Bauer LA, editor. Applied clinical pharmacokinetics. 3 ed. New York: McGraw-Hill; 2014."},{"key":"323_CR14","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/j.1528-1157.1959.tb04274.x","volume":"1","author":"F Buchthal","year":"1960","unstructured":"Buchthal F, Svensmark O. Aspects of the pharmacology of phenytoin (Dilantin) and phenobarbital relevant to their dosage in the treatment of epilepsy. Epilepsia. 1960;1:373\u201384.","journal-title":"Epilepsia"},{"key":"323_CR15","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1001\/archneur.1964.00460240074010","volume":"11","author":"H Kutt","year":"1964","unstructured":"Kutt H, Winters W, Kokenge R, McDowell F. Diphenylhydantoin metabolism, blood levels, and toxicity. Arch Neurol. 1964;11:642\u20138.","journal-title":"Arch Neurol"},{"key":"323_CR16","doi-asserted-by":"crossref","unstructured":"Lund L. Anticonvulsant effect of diphenylhydantoin relative to plasma levels. A prospective three-year study in ambulant patients with generalized epileptic seizures. Arch Neurol. 1974;31:289\u201394.","DOI":"10.1001\/archneur.1974.00490410037002"},{"key":"323_CR17","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1097\/00007691-199802000-00011","volume":"20","author":"M Chetty","year":"1998","unstructured":"Chetty M, Miller R, Seymour MA. Phenytoin auto-induction. Ther Drug Monit. 1998;20:60\u20132.","journal-title":"Ther Drug Monit"},{"key":"323_CR18","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1472-6947-12-7","volume":"12","author":"MD Krasowski","year":"2012","unstructured":"Krasowski MD, Penrod LE. Clinical decision support of therapeutic drug monitoring of phenytoin: measured versus adjusted phenytoin plasma concentrations. BMC Med Inform Decis Mak. 2012;12:7.","journal-title":"BMC Med Inform Decis Mak"},{"key":"323_CR19","first-page":"1","volume-title":"Applied pharmacokinetics: principles of therapeutic drug monitoring","author":"TN Tozer","year":"1992","unstructured":"Tozer TN, Winter ME. Phenytoin. In: Evans WE, Schentag JJ, Jusko WJ, editors. Applied pharmacokinetics: principles of therapeutic drug monitoring. 3rd ed. Vancouver: Applied Therapeutics; 1992. p. 1\u201344.","edition":"3"},{"key":"323_CR20","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1177\/1060028017707541","volume":"51","author":"VV Soriano","year":"2017","unstructured":"Soriano VV, Tesoro EP, Kane SP. Characterization of free phenytoin concentrations in end-stage renal disease using the Winter-Tozer equation. Ann Pharmacother. 2017;51:669\u201374.","journal-title":"Ann Pharmacother"},{"key":"323_CR21","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1177\/106002809703100301","volume":"31","author":"GD Anderson","year":"1997","unstructured":"Anderson GD, Pak C, Doane KW, Griffy KG, Temkin NR, Wilensky AJ, Winn HR. Revised Winter-Tozer equation for normalized phenytoin concentrations in trauma and elderly patients with hypoalbuminemia. Ann Pharmacother. 1997;31:279\u201384.","journal-title":"Ann Pharmacother"},{"key":"323_CR22","first-page":"269","volume":"69","author":"W Cheng","year":"2016","unstructured":"Cheng W, Kiang TKL, Bring P, Ensom MHH. Predictive performance of the Winter-Tozer and derivative equations for estimating free phenytoin concentration. Can J Hosp Pharm. 2016;69:269\u201379.","journal-title":"Can J Hosp Pharm"},{"key":"323_CR23","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1345\/aph.1R651","volume":"47","author":"SP Kane","year":"2013","unstructured":"Kane SP, Bress AP, Tesoro EP. Characterization of unbound phenytoin concentrations in neurointensive care unit patients using a revised Winter-Tozer equation. Ann Pharmacother. 2013;47:628\u201336.","journal-title":"Ann Pharmacother"},{"key":"323_CR24","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/jcph.417","volume":"55","author":"S Hennig","year":"2015","unstructured":"Hennig S, Norris R, Tu Q, van Breda K, Riney K, Foster K, Lister B, Charles B. Population pharmacokinetics of phenytoin in critically ill children. J Clin Pharmacol. 2015;55:355\u201364.","journal-title":"J Clin Pharmacol"},{"key":"323_CR25","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1111\/bcp.14053","volume":"85","author":"R ter Heine","year":"2019","unstructured":"ter Heine R, Kane SP, Huitema ADR, Krasowski MD, van Maarseveen EM. Nonlinear protein binding of phenytoin in clinical practice: development and validation of a mechanistic prediction model. Br J Clin Pharmacol. 2019;85:2360\u20138.","journal-title":"Br J Clin Pharmacol"},{"key":"323_CR26","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/j.1742-7843.2006.pto_309.x","volume":"99","author":"M Joerger","year":"2006","unstructured":"Joerger M, Huitema ADR, Boogerd W, van der Sande JJ, Schellens JHM, Beijnen JH. Interactions of serum albumin, valproic acid and carbamazepine with the pharmacokinetics of phenytoin in cancer patients. Basic Clin Pharmacol Toxicol. 2006;99:133\u201340.","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"323_CR27","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1177\/0883073813486294","volume":"29","author":"R ter Heine","year":"2014","unstructured":"ter Heine R, van Maarseveen EM, van der Westerlaken MML, Braun KPJ, Koudijs SM, ten Berg MJ, Malingre MM. The quantitative effect of serum albumin, serum urea, and valproic acid on unbound phenytoin concentrations in children. J Child Neurol. 2014;29:803\u201310.","journal-title":"J Child Neurol"},{"key":"323_CR28","doi-asserted-by":"crossref","unstructured":"Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604\u201312.","DOI":"10.7326\/0003-4819-150-9-200905050-00006"},{"key":"323_CR29","unstructured":"Siemens Dimension Vista\u00ae System Flex\u00ae reagent cartridge: phenytoin package insert. Siemens Healthcare Diagnostics Inc. 2017. Accessed 12 Jul 2020."},{"key":"323_CR30","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jchromb.2004.06.012","volume":"809","author":"J Chen","year":"2004","unstructured":"Chen J, Ohnmacht C, Hage DS. Studies of phenytoin binding to human serum albumin by high-performance affinity chromatography. J Chromatogr B Analyt Technol Biomed Life Sci. 2004;809:137\u201345.","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"323_CR31","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1046\/j.1365-2885.2002.00442.x","volume":"25","author":"PL Toutain","year":"2002","unstructured":"Toutain PL, Bousquet-Melou A. Free drug fraction vs free drug concentration: a matter of frequent confusion. J Vet Pharmacol Ther. 2002;25:460\u20133.","journal-title":"J Vet Pharmacol Ther"},{"key":"323_CR32","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2165\/11595650-000000000-00000","volume":"51","author":"FM Musteata","year":"2012","unstructured":"Musteata FM. Calculation of normalized drug concentrations in the presence of altered plasma protein binding. Clin Pharmacokinet. 2012;51:55\u201368.","journal-title":"Clin Pharmacokinet"},{"key":"323_CR33","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/01.ftd.0000184161.52573.0e","volume":"28","author":"B Charles","year":"2006","unstructured":"Charles B, Norris R, Xiao X, Hague W. Population pharmacokinetics of metformin in late pregnancy. Ther Drug Monit. 2006;28:67\u201372.","journal-title":"Ther Drug Monit"},{"key":"323_CR34","unstructured":"Model for individual covariates. In: Data, model and mapping. \u00a9Lixoft. 2018. https:\/\/monolix.lixoft.com\/data-and-models\/covariate\/. Accessed 12 Jul 2020."},{"key":"323_CR35","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1007\/s40262-019-00771-3","volume":"58","author":"Y Rong","year":"2019","unstructured":"Rong Y, Mayo P, Ensom MHH, Kiang TKL. Population pharmacokinetics of mycophenolic acid co-administered with tacrolimus in corticosteroid-free adult kidney transplant patients. Clin Pharmacokinet. 2019;58:1483\u201395.","journal-title":"Clin Pharmacokinet"},{"key":"323_CR36","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s13318-018-0525-3","volume":"44","author":"Y Rong","year":"2019","unstructured":"Rong Y, Mayo P, Ensom MHH, Kiang TKL. Population pharmacokinetic analysis of immediate-release oral tacrolimus co-administered with mycophenolate mofetil in corticosteroid-free adult kidney transplant recipients. Eur J Drug Metab Pharmacokinet. 2019;44:409\u201322.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"323_CR37","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1097\/FTD.0000000000000546","volume":"40","author":"PN Patsalos","year":"2018","unstructured":"Patsalos PN, Spencer EP, Berry DJ. Therapeutic drug monitoring of antiepileptic drugs in epilepsy: a 2018 update. Ther Drug Monit. 2018;40:526\u201348.","journal-title":"Ther Drug Monit"},{"key":"323_CR38","first-page":"333","volume-title":"Clinical pharmacokinetics","author":"ME Winter","year":"2017","unstructured":"Winter ME. Phenytoin and fosphenytoin. In: Murphy JE, editor. Clinical pharmacokinetics. 6th ed. Bethesda: American Society of Health-System Pharmacists; 2017. p. 333\u2013350.","edition":"6"},{"key":"323_CR39","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/BF03261928","volume":"51","author":"TKL Kiang","year":"2012","unstructured":"Kiang TKL, Sherwin CMT, Spigarelli MG, Ensom MHH. Fundamentals of population pharmacokinetic modelling: modelling and software. Clin Pharmacokinet. 2012;51:515\u201325.","journal-title":"Clin Pharmacokinet"},{"key":"323_CR40","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/BF03261932","volume":"51","author":"CMT Sherwin","year":"2012","unstructured":"Sherwin CMT, Kiang TKL, Spigarelli MG, Ensom MHH. Fundamentals of population pharmacokinetic modelling: validation methods. Clin Pharmacokinet. 2012;51:573\u201390.","journal-title":"Clin Pharmacokinet"},{"key":"323_CR41","first-page":"1813","volume-title":"Pharmacotherapy: principles and practice","author":"B Appendix","year":"2013","unstructured":"Appendix B. Common Laboratory Tests. In: Chisholm-Burns MA, Wells BG, Schwinghammer TL, Malone PM, Kolesar JM, Dipiro JT, editors. Pharmacotherapy: principles and practice. 3rd ed. New York: McGraw-Hill Education; 2013. p. 1813\u20131818.","edition":"3"},{"key":"323_CR42","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.5858\/arpa.2014-0464-CP","volume":"139","author":"PJ Howanitz","year":"2015","unstructured":"Howanitz PJ, Darcy TP, Meier FA, Bashleben CP. Assessing clinical laboratory quality: a College of American Pathologists Q-Probes study of prothrombin time INR structures, processes, and outcomes in 98 laboratories. Arch Pathol Lab Med. 2015;139:1108\u201314.","journal-title":"Arch Pathol Lab Med"},{"key":"323_CR43","doi-asserted-by":"crossref","unstructured":"Vossler DG, Weingarten M, Gidal BE, American Epilepsy Society Treatments Committee. Summary of antiepileptic drugs available in the United States of America: working toward a world without epilepsy. Epilepsy Curr. 2018;18:1\u201326.","DOI":"10.5698\/1535-7597.18.4s1.1"},{"key":"323_CR44","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.arcmed.2004.11.006","volume":"36","author":"L Aarons","year":"2005","unstructured":"Aarons L, Ahmed IA, Deleu D. Estimation of population pharmacokinetic parameters of free-phenytoin in adult epileptic patients. Arch Med Res. 2005;36:49\u201353.","journal-title":"Arch Med Res"},{"key":"323_CR45","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/cpt1976192135","volume":"19","author":"R Gugler","year":"1976","unstructured":"Gugler R, Manion CV, Azarnoff DL. Phenytoin: pharmacokinetics and bioavailability. Clin Pharmacol Ther. 1976;19:135\u201342.","journal-title":"Clin Pharmacol Ther"},{"key":"323_CR46","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1038\/psp.2013.14","volume":"2","author":"DR Mould","year":"2013","unstructured":"Mould DR, Upton RN. Basic concepts in population modeling, simulation, and model-based drug development-part 2: introduction to pharmacokinetic modeling methods. CPT Pharmacometrics Syst Pharmacol. 2013;2:e38.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"323_CR47","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/sj.clpt.6100241","volume":"82","author":"MO Karlsson","year":"2007","unstructured":"Karlsson MO, Savic RM. Diagnosing model diagnostics. Clin Pharmacol Ther. 2007;82:17\u201320.","journal-title":"Clin Pharmacol Ther"},{"key":"323_CR48","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1002\/phar.2273","volume":"39","author":"MC Montgomery","year":"2019","unstructured":"Montgomery MC, Chou JW, McPharlin TO, Baird GS, Anderson GD. Predicting unbound phenytoin concentrations: effects of albumin concentration and kidney dysfunction. Pharmacotherapy. 2019;39:756\u201366.","journal-title":"Pharmacotherapy"},{"key":"323_CR49","doi-asserted-by":"crossref","first-page":"355","DOI":"10.2165\/00003088-198308040-00006","volume":"8","author":"TH Grasela","year":"1983","unstructured":"Grasela TH, Sheiner LB, Rambeck B, Boenigk HE, Dunlop A, Mullen PW, Wadsworth J, Richens A, Ishizaki T, Chiba K, Miura H, Minagawa K, Blain PG, Mucklow JC, Bacon CT, Rawlins M. Steady-state pharmacokinetics of phenytoin from routinely collected patient data. Clin Pharmacokinet. 1983;8:355\u201364.","journal-title":"Clin Pharmacokinet"},{"key":"323_CR50","first-page":"188","volume":"72","author":"R Miller","year":"1987","unstructured":"Miller R, Rheeders M, Klein C, Suchet I. Population pharmacokinetics of phenytoin in South African black patients. S Afr Med J. 1987;72:188\u201390.","journal-title":"S Afr Med J"},{"key":"323_CR51","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1097\/FTD.0000000000000354","volume":"38","author":"LC Ku","year":"2016","unstructured":"Ku LC, Wu H, Greenberg RG, Hill KD, Gonzalez D, Hornik CP, Berezny A, Guptill JT, Jiang W, Zheng N, Cohen-Wolkowiez M, Melloni C. Use of therapeutic drug monitoring, electronic health record data, and pharmacokinetic modeling to determine the therapeutic index of phenytoin and lamotrigine. Ther Drug Monit. 2016;38:728\u201337.","journal-title":"Ther Drug Monit"},{"key":"323_CR52","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1159\/000500314","volume":"104","author":"S Alqahtani","year":"2019","unstructured":"Alqahtani S, Alzaidi T, Alotaibi M, Alsultan A. Estimation of phenytoin pharmacokinetic parameters in Saudi epileptic patients. Pharmacology. 2019;104:60\u20136.","journal-title":"Pharmacology"},{"key":"323_CR53","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1248\/bpb.19.444","volume":"19","author":"A Odani","year":"1996","unstructured":"Odani A, Hashimoto Y, Takayanagi K, Otsuki Y, Koue T, Takano M, Yasuhara M, Hattori H, Furusho K, Inui K. Population pharmacokinetics of phenytoin in Japanese patients with epilepsy: analysis with a dose-dependent clearance model. Biol Pharm Bull. 1996;19:444\u20138.","journal-title":"Biol Pharm Bull"},{"key":"323_CR54","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1365-2710.1994.tb00681.x","volume":"19","author":"R Ismail","year":"1994","unstructured":"Ismail R, Rahman AFA, Chand P. Pharmacokinetics of phenytoin in routine clinic patients in Malaysia. J Clin Pharm Ther. 1994;19:245\u20138.","journal-title":"J Clin Pharm Ther"},{"key":"323_CR55","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1046\/j.1468-1331.1999.630331.x","volume":"6","author":"M Abduljabbar","year":"1999","unstructured":"Abduljabbar M, Al-Khamis K, Ogunniyi A, Daif AK, Al-Yamani M. Phenytoin dosage adjustment in Saudi epileptics: utilization of steady-state pharmacokinetic parameters. Eur J Neurol. 1999;6:331\u20134.","journal-title":"Eur J Neurol"},{"key":"323_CR56","doi-asserted-by":"crossref","first-page":"217","DOI":"10.4103\/jrpp.JRPP_17_58","volume":"6","author":"S Alimardani","year":"2017","unstructured":"Alimardani S, Sadrai S, Masoumi HT, Salari P, Najafi A, Eftekhar B, Mojtahedzadeh M. Pharmacokinetic behavior of phenytoin in head trauma and cerebrovascular accident patients in an Iranian population. J Res Pharm Pract. 2017;6:217\u201322.","journal-title":"J Res Pharm Pract"},{"key":"323_CR57","doi-asserted-by":"crossref","first-page":"62","DOI":"10.4103\/0975-8453.59514","volume":"1","author":"HV Chavda","year":"2010","unstructured":"Chavda HV, Patel CN, Anand IS. Biopharmaceutics classification system. Sys Rev Pharm. 2010;1:62\u20139.","journal-title":"Sys Rev Pharm"},{"key":"323_CR58","doi-asserted-by":"crossref","first-page":"5280","DOI":"10.3390\/nu6115280","volume":"6","author":"M Ebadi","year":"2014","unstructured":"Ebadi M, Mazurak VC. Evidence and mechanisms of fat depletion in cancer. Nutrients. 2014;6:5280\u201397.","journal-title":"Nutrients"},{"key":"323_CR59","first-page":"130","volume":"10","author":"DR Weber","year":"2012","unstructured":"Weber DR, Leonard MB, Zemel BS. Body composition analysis in the pediatric population. Pediatr Endocrinol Rev. 2012;10:130\u20139.","journal-title":"Pediatr Endocrinol Rev"},{"key":"323_CR60","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1016\/j.xphs.2018.03.023","volume":"107","author":"AN Deitchman","year":"2018","unstructured":"Deitchman AN, Singh RSP, Derendorf H. Nonlinear protein binding: not what you think. J Pharm Sci. 2018;107:1754\u201360.","journal-title":"J Pharm Sci"},{"key":"323_CR61","first-page":"159","volume-title":"Albumin: structure, function and uses","author":"EM Sellers","year":"1977","unstructured":"Sellers EM, Koch-Weser J. Clinical implications of drug-albumin interaction. In: Rosenoer VM, Oratz M, Rothschild MA, editors. Albumin: structure, function and uses. 1st ed. Oxford: Pergamon Press; 1977. p. 159\u2013182.","edition":"1"},{"key":"323_CR62","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1007\/s00228-008-0553-z","volume":"64","author":"RK Verbeeck","year":"2008","unstructured":"Verbeeck RK. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol. 2008;64:1147\u201361.","journal-title":"Eur J Clin Pharmacol"},{"key":"323_CR63","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1159\/000184949","volume":"48","author":"H Mabuchi","year":"1988","unstructured":"Mabuchi H, Nakahashi H. A major inhibitor of phenytoin binding to serum protein in uremia. Nephron. 1988;48:310\u20134.","journal-title":"Nephron"},{"key":"323_CR64","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1159\/000168708","volume":"14","author":"A Dasgupta","year":"1994","unstructured":"Dasgupta A, Malik S. Fast atom bombardment mass spectrometric determination of the molecular weight range of uremic compounds that displace phenytoin from protein binding: absence of midmolecular uremic toxins. Am J Nephrol. 1994;14:162\u20138.","journal-title":"Am J Nephrol"},{"key":"323_CR65","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1007\/s00228-014-1709-7","volume":"70","author":"KJ Barnes","year":"2014","unstructured":"Barnes KJ, Rowland A, Polasek TM, Miners JO. Inhibition of human drug-metabolising cytochrome P450 and UDP-glucuronosyltransferase enzyme activities in vitro by uremic toxins. Eur J Clin Pharmacol. 2014;70:1097\u2013106.","journal-title":"Eur J Clin Pharmacol"},{"key":"323_CR66","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/clpt.1981.10","volume":"29","author":"RF Leonard","year":"1981","unstructured":"Leonard RF, Knott PJ, Rankin GO, Robinson DS, Melnick DE. Phenytoin-salicylate interaction. Clin Pharmacol Ther. 1981;29:56\u201360.","journal-title":"Clin Pharmacol Ther"},{"key":"323_CR67","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1684\/epd.2014.0714","volume":"16","author":"G Zaccara","year":"2014","unstructured":"Zaccara G, Perucca E. Interactions between antiepileptic drugs, and between antiepileptic drugs and other drugs. Epileptic Disord. 2014;16:409\u201331.","journal-title":"Epileptic Disord"},{"key":"323_CR68","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2165\/00003088-199018010-00003","volume":"18","author":"RL Nation","year":"1990","unstructured":"Nation RL, Evans AM, Milne RW. Pharmacokinetic drug interactions with phenytoin (Part I). Clin Pharmacokinet. 1990;18:37\u201360.","journal-title":"Clin Pharmacokinet"},{"key":"323_CR69","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/BF03189395","volume":"4","author":"M Lecomte","year":"1979","unstructured":"Lecomte M, Zini R, d'Athis P, Tillement JP. Phenytoin binding to human albumin. Eur J Drug Metab Pharmacokinet. 1979;4:23\u20138.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"323_CR70","doi-asserted-by":"crossref","unstructured":"C\u00e9spedes-Garro C, Fricke-Galindo I, Naranjo MEG, Rodrigues-Soares F, Fari\u00f1as H, de Andr\u00e9s F, L\u00f3pez-L\u00f3pez M, Pe\u00f1as-Lled\u00f3 EM, LLerena A. Worldwide interethnic variability and geographical distribution of CYP2C9 genotypes and phenotypes. Expert Opin Drug Metab Toxicol. 2015;11:1893\u2013905.","DOI":"10.1517\/17425255.2015.1111871"},{"key":"323_CR71","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0920-1211(99)00017-0","volume":"35","author":"AE Rettie","year":"1999","unstructured":"Rettie AE, Haining RL, Bajpai M, Levy RH. A common genetic basis for idiosyncratic toxicity of warfarin and phenytoin. Epilepsy Res. 1999;35:253\u20135.","journal-title":"Epilepsy Res"},{"key":"323_CR72","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.cbi.2016.04.040","volume":"253","author":"LG Chen","year":"2016","unstructured":"Chen LG, Wang Z, Zhu Y, Xiong JH, Sun LR, Dai DP, Cai JP, Hu GX. In vitro metabolism of phenytoin in 36 CYP2C9 variants found in the Chinese population. Chem Biol Interact. 2016;253:93\u20139.","journal-title":"Chem Biol Interact"},{"key":"323_CR73","doi-asserted-by":"crossref","unstructured":"Caudle KE, Rettie AE, Whirl-Carrillo M, Smith LH, Mintzer S, Lee MTM, Klein TE, Callaghan JT, Clinical Pharmacogenetics Implementation Consortium. Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosing. Clin Pharmacol Ther. 2014;96:542\u20138.","DOI":"10.1038\/clpt.2014.159"},{"key":"323_CR74","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s00228-010-0817-2","volume":"66","author":"R Kesavan","year":"2010","unstructured":"Kesavan R, Narayan SK, Adithan C. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on phenytoin-induced neurological toxicity in Indian epileptic patients. Eur J Clin Pharmacol. 2010;66:689\u201396.","journal-title":"Eur J Clin Pharmacol"},{"key":"323_CR75","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1111\/j.1468-1331.2011.03361.x","volume":"18","author":"C Depondt","year":"2011","unstructured":"Depondt C, Godard P, Espel RS, Da Cruz AL, Lienard P, Pandolfo M. A candidate gene study of antiepileptic drug tolerability and efficacy identifies an association of CYP2C9 variants with phenytoin toxicity. Eur J Neurol. 2011;18:1159\u201364.","journal-title":"Eur J Neurol"},{"key":"323_CR76","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1177\/0091270009343006","volume":"49","author":"S Hennessy","year":"2009","unstructured":"Hennessy S, Leonard CE, Freeman CP, Metlay JP, Chu X, Strom BL, Bilker WB. CYP2C9, CYP2C19, and ABCB1 genotype and hospitalization for phenytoin toxicity. J Clin Pharmacol. 2009;49:1483\u20137.","journal-title":"J Clin Pharmacol"},{"key":"323_CR77","doi-asserted-by":"crossref","first-page":"5405","DOI":"10.1016\/j.bbagen.2013.03.026","volume":"1830","author":"U Kragh-Hansen","year":"2013","unstructured":"Kragh-Hansen U, Minchiotti L, Galliano M, Peters T Jr. Human serum albumin isoforms: genetic and molecular aspects and functional consequences. Biochim Biophys Acta. 2013;1830:5405\u201317.","journal-title":"Biochim Biophys Acta"}],"container-title":["Drugs in R&D"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-020-00323-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40268-020-00323-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-020-00323-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,6]],"date-time":"2021-10-06T19:35:06Z","timestamp":1633548906000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40268-020-00323-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,7]]},"references-count":77,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["323"],"URL":"https:\/\/doi.org\/10.1007\/s40268-020-00323-2","relation":{},"ISSN":["1174-5886","1179-6901"],"issn-type":[{"value":"1174-5886","type":"print"},{"value":"1179-6901","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,7]]},"assertion":[{"value":"19 September 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Heajin Jun was supported by the International Research & Development Program of the National Research Foundation of Korea (Ministry of Science and ICT grant #2019K1A3A1A73079569) and a MITACS Globalink Research Grant (#FR41232) awarded to Heajin Jun and Tony KL Kiang.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Heajin Jun, Yan Rong, Catharina Yih, Jordan Ho, Wendy Cheng, and Tony KL Kiang have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Reasonable requests to access the data should be directed to the corresponding author (Tony KL Kiang, tkiang@ualberta.ca).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"MonolixSuite-2019R2 (Lixoft SAS, Antony, France) and Rsmlx package (Rsmlx, version 2.0.2, Xpop Inria Team) R software v3.6.3 (R Core Team, Vienna, Austria) were used. Requests to access the custom codes for protein-binding models should be directed to the corresponding author (Tony KL Kiang, tkiang@ualberta.ca).","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"The study protocol was approved by the University of British Columbia (H18-02215) and the University of Alberta (Pro00100357) research ethics boards. The study was performed in accordance with all ethical standards outlined in the 1964 Declaration of Helsinki and its later amendments.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"As this was a retrospective study, neither consent to participate nor consent to publish were required.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent"}},{"value":"Wendy Cheng and Tony Kiang conceived the original study design. Retrospective data collection was conducted by Jordan Ho as part of his pharmacy residency project (supervised by Wendy Cheng [primary mentor], Catharina Yih, and Tony Kiang). Non-linear mixed-effects modeling was conducted by Heajin Jun, Yan Rong, and Tony Kiang. The manuscript was drafted by Heajin Jun and Tony Kiang. All listed authors provided feedback and commentary on the submitted draft.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}